Hypertension optimal treatment (HOT) study: Successes and failures

Cardiovascular Reviews and Reports

Volumn 20, Issue 4, 1999, Pages 232-236

  Sica, Domenic A ^a   Frishman, William ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WESTCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FELODIPINE; HYDROCHLOROTHIAZIDE;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; HUMAN; HYPERTENSION; MORTALITY; TREATMENT OUTCOME;

EID: 0032935496     PISSN: 01973118     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Hansson L, Hedner T, Dahlof B. Prospective Randomized Open Blinded End point (PROBE) Study: A novel design for interventions trials. Blood Press. 1992;1:113-119.
2. Hansson L, Zanchetti A, Carruthers SG, et al. Effect of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1998;351:1755-1762.
3. Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering blood pressure. Lancet. 1987;1:581-584.
4. Farnett L, Mulrow CD, Linn WD, et al. The J curve phenomenon and the treatment of hypertension. Is there a point beyond which blood pressure reduction is dangerous? JAMA. 1991;265.489-495.
5. Pocock SJ, Simon R. Sequential treatment regimens with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:103-115
6. Guazzi MD, Campodonico J, Celeste F, et al. Antihypertensive efficacy of angiotensin converting enzyme inhibition and aspirin counteraction. Clin Pharmacol 1998;63:79-86.
7. Sica DA, Gehr TWB. Dose-response relationship and dose adjustments. In: Izzo J, Black ER (eds). Hypertension Primer, 2nd edition. Philadelphia, PA: Williams and Wilkins, 1998:342-344.
8. Hansson L, Zanchetti AA, for the HOT study Group. The hypertension optimal treatment (HOT) study. 12 months data on blood pressure and tolerability, with special reference to age and gender. Blood Press. 1995;4:313-319.
9. Ruilope LM, Hansson L, Zanchetti A. Renal aspects of the Hypertension Optimal Treatment (HOT) Study. J Nephrol. 1996;9:147-151.
10. Sica DA, Ripley E. Low dose fixed-dose combination therapy. In: Oparil S, Weber M (eds). Hypertension. 1st edition. Philadelphia, PA: W.B. Saunders Inc.; in press.
11. Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998;21:597-600.
12. Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril in patients with non-insulin dependent diabetes and hypertension. N Engl J Med. 1998;338:645-652.
13. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Ann Intern Med. 1997;157:2413-2446.
14. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. Prevention of death, myocardial infarction and stroke by prolonged antiplatetet therapy in various categories of patients. BMJ. 1994;308:81-106.
15. He J, Whelton PK, Vu B, et al. Aspirin and risk of hemorrhagic stroke. JAMA. 1998;280:1930-1935.
16. Wiklund J, Halling K, Ryden-Bergsten T, et al, on behalf of the HOT study Group. Does lowering the blood pressure improve the mood: Quality of life results from the Hypertension Optimal Treatment (HOT) Study. Blood Press. 1997;6:357-364.
17. Kannel WB, Wolff PA, Verter J, et al. Epidemiologic assessment of the role of blood pressure in stroke: The Framingham Study. JAMA. 1970;214:301-310.
18. Fletcher AE, Bulpitt CJ. How far should blood pressure be lowered? N Engl J Med. 1992;326:251-254.
19. MacMahon SW, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged difference in blood pressure: Prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-774.
20. Flack JM, Neaton J, Grimm R Jr, et al. Blood pressure and mortality among men with prior myocardial infarction. Circulation. 1995,92:2437-2445.